Curis (NASDAQ:CRIS) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Curis (NASDAQ:CRIS – Free Report) in a research note published on Monday, MarketBeat reports. HC Wainwright currently has a $17.00 price target on the biotechnology company’s stock. Separately, StockNews.com began coverage on Curis in a report on Friday. They set a “hold” rating on the stock. […]
HC Wainwright reiterated their buy rating on shares of Curis (NASDAQ:CRIS – Free Report) in a research note published on Monday, MarketBeat reports. HC Wainwright currently has a $17.00 price target on the biotechnology company’s stock. Separately, StockNews.com began coverage on Curis in a report on Friday. They set a “hold” rating on the stock. […]
